CEO Mark Capone looks at the pioneering role Myriad is playing a as we enter the golden era of molecular diagnostics and what he envisions for our future. “In the next five years, there will be incredible discoveries and we are going to transform the lives of our patients around the world in ways that were not envisioned even only a few years ago.”